| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10137580 | International Immunopharmacology | 2018 | 10 Pages |
Abstract
The proposed mechanism of action for silymarin and lisinopril in interfering with NFκB pathway. DAG, diacyl glycerol; IkB, inhibitory kappa B protein; IKK, IκB kinase; MMP-2, matrix metalloproteinase 2; NFkB, nuclear transcription factor kappa B; PKC, protein kinase C; PLC, phospholipase C; TGF-β, transforming growth factor beta; TIMP-1, tissue inhibitor of metalloproteinase 1; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.215
Keywords
HBSSRASALTα-SMAMMP-2CCl4GSHTIMP-1DMEMMDATGF-βDulbecco's modified Eagle MediumMTTNFκBNOxASTAspartate aminotransferaseAlanine aminotransferasealpha smooth muscle actinALPAlkaline phosphatasetissue inhibitor of metalloproteinase-1Transforming growth factor beta-1tumor necrosis factor alphaSODSuperoxide dismutaseRenin angiotensin systemrenin-angiotensin systemSilymarinVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)TNF-αFibrosisLisinoprilMatrix metalloproteinase-2malondialdehydeHank's balanced salt solutionreduced glutathione
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sameh Saber, Reham Goda, Ghada S. El-Tanbouly, Dalia Ezzat,